Business Overview: Evofem Biosciences, Inc. (OTCQB: EVFM)

---

Executive Summary

Evofem Biosciences, Inc. is a San Diego-based, commercial-stage biopharmaceutical company focused on sexual and reproductive health. Its flagship product, PHEXXI, is the first and only FDA-approved, hormone-free prescription contraceptive vaginal gel, approved in May 2020 and launched commercially in September 2020. In October 2022, Evofem halted all further clinical development to concentrate entirely on growing PHEXXI sales — a strategic pivot reflecting the company's financial constraints.

Evofem is a company in genuine financial distress: it trades on the OTCQB (with risk of demotion to OTC Pink for non-compliance with listing standards), discloses going-concern risk, received a Notice of Default from a manufacturing/financial partner (Future Pak, LLC) with the cancellation of a Forbearance Agreement and possible legal action, and has a pending merger with Aditxt, Inc. that has been terminated, reinstated, and amended multiple times — most recently with a consummation deadline of September 30, 2025. In July 2024 Evofem acquired global rights to a second product, SOLOSEC, and relaunched it in the U.S. in November 2024, in an effort to diversify revenue using its existing sales infrastructure.

---

1. Core Business Model & How They Work

Evofem sells prescription women's health products through a small, targeted U.S. sales force supplemented by telehealth access, while licensing/partnering for revenue outside the U.S.

[ FDA-Approved Product (PHEXXI/SOLOSEC) ] ➡️ [ Direct Sales Force (16 reps) Targets OB/GYNs ] ➡️ [ Telehealth Platform Connects Patients to Providers ] ➡️ [ Prescription Filled/Mailed ] ➡️ [ Ex-U.S. Revenue via Licensing/Partners (e.g., Pharma 1 in Middle East) ]

Key Operational Drivers

1. PHEXXI — core hormone-free contraceptive: A prescription vaginal gel used 0–60 minutes before intercourse that works by maintaining vaginal pH to reduce sperm motility, marketed as a non-hormonal alternative to pills, patches, rings, and IUDs. Approved in Nigeria (as Femidence) with submissions pending in Mexico, Ethiopia, and Ghana.
2. SOLOSEC — newly acquired second product: Global rights acquired July 2024; a single-dose oral antimicrobial for bacterial vaginosis and trichomoniasis, relaunched in the U.S. in November 2024 to diversify revenue beyond PHEXXI alone.
3. Lean, targeted commercial model: A small direct sales force (16 regional representatives as of March 2025) targets OB/GYN prescribers, supported by a telehealth platform that connects patients to providers and facilitates prescription fulfillment by mail.
4. Outsourced manufacturing: PHEXXI manufacturing is outsourced to third parties; SOLOSEC has a committed supply arrangement through November 2026.
5. Ex-U.S. licensing strategy: International revenue comes through partnerships (e.g., Pharma 1 holds Middle East rights to PHEXXI, supplied by Evofem at cost-plus) rather than direct Evofem commercial operations abroad.
6. Portfolio expansion intent: Management has stated plans to in-license or acquire additional launch-ready products to better utilize its existing sales force and diversify revenue beyond its two current products.

---

2. Product Portfolio

---

3. Competitive Landscape

Evofem's own "Contraceptive Market Landscape" discussion frames PHEXXI's competition across three categories:

            HORMONAL CONTENT
            Hormonal                        Non-hormonal
High  ┌─────────────────────────────┬─────────────────────────────┐
Duration│ Nexplanon, Depo-Provera,    │ Paragard (copper IUD)         │
(long)  │ Mirena/Kyleena/Skyla (IUDs) │                               │
      ├─────────────────────────────┼─────────────────────────────┤
Short  │ Twirla, Xulane (patches),    │ PHEXXI (EVOFEM), Opill (OTC), │
Duration│ Annovera (ring)              │ condoms (Trojan, Durex)        │
      └─────────────────────────────┴─────────────────────────────┘

Competitors by Category

1. Short-acting hormonal methods: Pills, patches (Twirla, Xulane), and rings (Annovera) — the traditional, well-established hormonal contraceptive options PHEXXI's "hormone-free" positioning is designed to differentiate against.
2. Long-acting reversible contraception (LARC): IUDs (Paragard, Kyleena, Skyla, Mirena), Nexplanon (implant), and Depo-Provera (injection) — higher-efficacy, lower-frequency alternatives that compete for the same contraceptive-choice decision, generally with stronger real-world efficacy than on-demand methods.
3. OTC methods: Condoms (Trojan, Durex) and Opill, the progestin-only birth control pill that became available over-the-counter in 2024 — a significant new competitive threat, since Opill offers a non-prescription, likely lower-friction alternative in the same "simple, accessible" contraceptive positioning PHEXXI has pursued.

For SOLOSEC, Evofem notes that less expensive generic competitors in its drug class create additional prior-authorization barriers that can limit insurance coverage and reimbursement.

---

4. Strategic Strengths & Risks

Strengths

• First/only-in-category positioning: PHEXXI's status as the first and only FDA-approved hormone-free prescription contraceptive gel gives it a genuine clinical differentiation point for patients seeking non-hormonal options.
• Diversification into SOLOSEC: Acquiring a second, already-approved product lets Evofem leverage its existing sales force and telehealth infrastructure without needing a second clinical development program.
• Lean commercial infrastructure: A small, focused sales force and telehealth-enabled fulfillment model keeps commercial costs lower than a traditional large pharma sales organization.

Risks — Severe and Immediate

1. Going-concern risk: The company explicitly discloses substantial doubt about its ability to continue as a going concern, the most serious financial risk disclosure a public company can make.
2. OTCQB listing risk: Common stock trades on the OTCQB with risk of demotion to OTC Pink if the company fails to regain listing compliance — a further signal of financial and governance distress.
3. Default and forbearance breakdown: A Notice of Default from Future Pak, LLC and cancellation of a related Forbearance Agreement, with possible legal action, represents an acute near-term financial/legal threat.
4. Pending, repeatedly-amended merger: The proposed merger with Aditxt, Inc. has been terminated, reinstated, and amended multiple times, with a (as of the most recent amendment) consummation deadline of September 30, 2025 — reflecting significant uncertainty about Evofem's corporate future and standalone viability.
5. New OTC competitor (Opill): Opill's 2024 switch to over-the-counter availability directly threatens PHEXXI's positioning as a simple, accessible non-hormonal option, since Opill (while hormonal) removes the prescription-access friction PHEXXI still requires.
6. Generic pressure on SOLOSEC: Lower-cost generics in SOLOSEC's drug class create prior-authorization and reimbursement hurdles that could limit its commercial uptake.

---

5. Financial Overview

---

6. Summary Conclusion

Evofem Biosciences holds a genuinely differentiated clinical asset in PHEXXI — the only FDA-approved hormone-free prescription contraceptive gel — and has taken a sensible diversification step by acquiring and relaunching SOLOSEC to better utilize its existing commercial infrastructure. But the company's disclosed financial condition is severe: explicit going-concern risk, an OTCQB listing at risk of further demotion, a default notice from a key financial/manufacturing partner, and a repeatedly renegotiated merger agreement with Aditxt whose outcome remains unresolved. Evofem's biggest forward risk is not really competitive — though Opill's 2024 OTC launch and generic pressure on SOLOSEC both matter — it is existential: whether the company can resolve its financial distress and complete (or otherwise navigate) its pending corporate transaction before its going-concern risk becomes an actual inability to continue operating.